同方康泰(01312.HK)附屬與山西工業訂立陝西建築合約
格隆匯7月12日丨同方康泰(01312.HK)公吿,於2021年7月12日,陝西紫光(公司的間接非全資附屬公司)與山西工業訂立陝西建築合約,據此陝西紫光同意委聘山西工業作為總承包商以進行陝西生產基地項目的建築工程,估計合約價為人民幣1.66億元(可予調整)。
根據陝西建築合約,山西工業(作為總承包商)負責建築陝西生產基地項目的主要建設綜合樓、兩處生產工廠、倉庫、車間及其他配套設施,包括但不限於陝西生產基地的主體建築工程、消防工程及設備、供水及渠務、電力工程、通風及空調、裝修及裝飾。
鑑於集團的長遠發展,董事會決定建立新的中藥生產基地。董事會認為藉助更先進及自動化的機器,陝西生產基地的建立將提升集團的中藥產能,令集團可擴大產品組合,從而提高集團的生產效率,同時降低成本。董事會認為,建設陝西生產基地符合集團的整體策略,將有利於其醫藥板塊的長期業務發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.